Lakefront Biotherapeutics American Depositary Shares
LKFT
75 hedge funds and large institutions have $801M invested in Lakefront Biotherapeutics American Depositary Shares in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 7 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 22
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
14% more capital invested
Capital invested by funds: $704M → $801M (+$97.5M)
2.27% more ownership
Funds ownership: 27.64% → 29.91% (+2.3%)
1% more funds holding
Funds holding: 74 → 75 (+1)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
55% less call options, than puts
Call options by funds: $6.39M | Put options by funds: $14.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$61.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$14M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$6.82M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.73M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$11.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.97M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.08M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.06M |
| 5 |
Morgan Stanley
New York
|
-$2.95M |
LKFT Hedge Fund Activity: Q2 2023 in Review
75 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2023, worth a combined $801M — up 14% from $704M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LKFT positions and 7 closed out — a net gain of 1 holder — while 29 added to existing stakes and 22 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $61.7M. The largest seller was Millennium Management, cutting an estimated $11.2M.
- 75 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2023, up from 74 in Q1 2023.
- Funds reported $801M of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2023, up 14% quarter-over-quarter.
- 8 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2023 and 7 closed out, a net change of +1 holder.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2023 was EcoR1 Capital, an estimated $61.7M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q2 2023 was Millennium Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q2 2023.